Bugworks Research Inc. is a clinical stage biopharmaceutical company focused on developing novel therapies against infectious diseases and cancer. The company is dedicated to addressing the global health challenges posed by antimicrobial resistance (AMR) and cancer through innovative solutions.

Bugworks Research Inc.

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

Celebrating a decade of innovation-driven research to address two major health issues afflicting humanity - #antimicrobialresistance and #cancer.
Bugworks is delighted to present a visual capsule of our journey thus far.

https://lnkd.in/duEiCizG

#amr #drugresistance #superbugs #drugdiscovery #drugdevelopment #innovation #cancer #immunooncology
#tumourmicroenvironment #affordability #accessibility
#translationalresearch #healthcare

📣 Bugworks has recently been featured in the Times of India, highlighting the global impact of antimicrobial resistance (AMR) and the innovative research conducted in India to combat this global pandemic. We are grateful to the Times of India for bringing attention to this critical issue and the groundbreaking work being done to combat it.

#antimicrobialresistance #AMR #innovation #antibioticresistance 
https://lnkd.in/ghf3wp5X

Bugworks is at the forefront of inventing differentiated, affordable and accessible solutions to tackle two significant global health challenges.

1. Novel antibiotics to address untreatable superbugs.
2. Novel solutions for hard-to-treat solid cell tumours.

Anand Anandkumar Santanu Datta Bala Subramanian Shahul Hameed P Vasan Sambandamurthy Leela Maitreyi Harish Kaushik Kotakonda, PhD 
UTEC - The University of Tokyo Edge Capital Partners 3one4 Capital Lightrock India Global Antibiotic R&D Partnership (GARDP) Centre for Cellular and Molecular Platforms (C-CAMP) Global Brain Corporation CARB-X 
#antimicrobialresistance #antimicrobialstewardship #immunooncology #oncology #targetedtherapy

✨The first baby steps into the daunting field of cancer ✨

We are thrilled to share that our team is presenting a poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023
🌍

📍 Location: Geneva, Switzerland
🔍 Poster Title: "Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are efficacious in high adenosine tumor microenvironment"


https://lnkd.in/gqHCcqhJ

📣  Raising Awareness on Antimicrobial Resistance (AMR): Our Latest Article by Dr Vasanthi Ramachandran is Live! 💊

This AMR Awareness Week, we delve into the pressing need for innovation in antibiotics research and development. 💡 
🔗https://lnkd.in/g_Nr2-zd 

Let's work together to promote change, initiate discussions, and drive advancements that will ensure the development of effective treatments for the benefit of future generations.

 #AMRAwareness #InnovationInHealthcare #AntibioticsResearch #HealthForAll #InvestInHealthcareInnovation #antimicrobialresistance #antimicrobialstewardship

🏆 Celebrating: Bugworks Research India Pvt. Ltd. Wins an Award for Patent Portfolio in the Startup Segment! 🏆

Bugworks Research India Pvt. Ltd. won the runner-up award for Patents Portfolio in the Startup segment at the “CII Industrial IP Awards 2023”. We are greatly encouraged by the recognition and will strive to bring forth valuable, affordable and accessible solutions to combat AMR and Cancer worldwide.” 
 
Pic (L to R): Mr Vipin Sondhi, Chairman CII; Ms Pratibha Singh, Justice High Court, Delhi; Dr R. A. Mashelkar, former DG, CSIR & Chairman, Grand Jury CII IP Awards 2023; Dr V. Balasubramanian, COO, Bugworks Research India Pvt. Ltd. and Mr R. Saha, Senior Advisor, CII
 
#cii #ciipr #AwardWinners #ProudMoment #CompanyAchievement #InnovationInBusiness #Bugworks

Dr Anand Anandkumar, Our CEO, is set to grace the virtual stage as a speaker in an upcoming webinar!

📅 Date and Time: 21 November 2023, 5:30-7 PM IST
🖥️ Webinar Title: Rejuvenating The Global Antibiotic Innovation Ecosystem: The Way Forward

Let's unite for an enriching session that promises inspiration and strategic wisdom.

The World Anti-Microbial Resistance Congress is coming up! Our CEO, Dr. Anand Anandkumar, will discuss the importance of the LMICs in finding solutions to the AMR. We hope to see many of you there!

We’re delighted to announce that Bugworks Research Inc. and Global Antibiotic R&D Partnership (GARDP) are joining forces to accelerate the development of a novel antibiotic to treat serious bacterial infections. 

"We are thrilled to strengthen our ongoing partnership with GARDP to accelerate the clinical development of BWC0977 and deliver a truly differentiated broad-spectrum drug that can tackle the toughest drug-resistant superbugs."

This compound aims to treat patients with serious bacterial infections in critical care and community settings. 

Read the announcement: https://lnkd.in/di5gZM6W

#AMR #antibioticresistance #antimicrobialresistance #researchanddevelopment #drugdevelopment

We are delighted a proud that our CEO Dr. Anand Anandkumar has been awarded the “Entrepreneur of the Year 2021-22” by BioSpectrum India 

#entrepreneurship #AMR #antimicrobialresistance #leadership #awardsforexcellence #ceo

Metric
Company Name	Bugworks Research Inc.
Symbol
MSH ID	COM:BUGWORKSRESEARCH
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	IN
Stage
Employee Count	43
Website	bugworksresearch.com
LinkedIn	bugworks
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.36
28-Day Growth Score	16.39
90-Day Growth Score	14.09
365-Day Growth Score	13.03

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BUGWORKSRESEARCH

Bugworks Research Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue